Inhibition of PIP4Kγ ameliorates the pathological effects of mutant huntingtin protein.

Autor: Al-Ramahi I; Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, United States.; Baylor College of Medicine, Texas Medical Center, Houston, United States., Giridharan SSP; Department of Cell and Developmental Biology, Life Sciences Institute, University of Michigan, Ann Arbor, United States., Chen YC; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, United States., Patnaik S; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, United States., Safren N; Department of Neurology, University of Michigan, Ann Arbor, United States., Hasegawa J; Department of Cell and Developmental Biology, Life Sciences Institute, University of Michigan, Ann Arbor, United States., de Haro M; Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, United States.; Baylor College of Medicine, Texas Medical Center, Houston, United States., Wagner Gee AK; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, United States., Titus SA; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, United States., Jeong H; The Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, United States., Clarke J; Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom., Krainc D; The Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, United States., Zheng W; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, United States., Irvine RF; Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom., Barmada S; Department of Neurology, University of Michigan, Ann Arbor, United States., Ferrer M; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, United States., Southall N; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, United States., Weisman LS; Department of Cell and Developmental Biology, Life Sciences Institute, University of Michigan, Ann Arbor, United States., Botas J; Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, United States.; Baylor College of Medicine, Texas Medical Center, Houston, United States., Marugan JJ; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, United States.
Jazyk: angličtina
Zdroj: ELife [Elife] 2017 Dec 26; Vol. 6. Date of Electronic Publication: 2017 Dec 26.
DOI: 10.7554/eLife.29123
Abstrakt: The discovery of the causative gene for Huntington's disease (HD) has promoted numerous efforts to uncover cellular pathways that lower levels of mutant huntingtin protein (mHtt) and potentially forestall the appearance of HD-related neurological defects. Using a cell-based model of pathogenic huntingtin expression, we identified a class of compounds that protect cells through selective inhibition of a lipid kinase, PIP4Kγ. Pharmacological inhibition or knock-down of PIP4Kγ modulates the equilibrium between phosphatidylinositide (PI) species within the cell and increases basal autophagy, reducing the total amount of mHtt protein in human patient fibroblasts and aggregates in neurons. In two Drosophila models of Huntington's disease, genetic knockdown of PIP4K ameliorated neuronal dysfunction and degeneration as assessed using motor performance and retinal degeneration assays respectively. Together, these results suggest that PIP4Kγ is a druggable target whose inhibition enhances productive autophagy and mHtt proteolysis, revealing a useful pharmacological point of intervention for the treatment of Huntington's disease, and potentially for other neurodegenerative disorders.
Databáze: MEDLINE
Externí odkaz: